K. Dang

发表

Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies

A. Boudreau, N. Trinklein, O. Vafa, 2019, mAbs.

Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release

A. Boudreau, N. Trinklein, S. Kwek, 2021, Journal for ImmunoTherapy of Cancer.

CD38 ecto-enzyme in immune cells is induced during aging regulating NAD+ and NMN levels

J. Rabinowitz, J. Baur, J. Sedivy, 2020, Nature Metabolism.

TNB-738, a biparatopic antibody, boosts intracellular NAD+ by inhibiting CD38 ecto-enzyme activity

A. Poupon, E. Chini, M. Cuturi, 2022, mAbs.

Sequence-Based Discovery Demonstrates That Fixed Light Chain Human Transgenic Rats Produce a Diverse Repertoire of Antigen-Specific Antibodies

Michael J. Osborn, A. Boudreau, N. Trinklein, 2018, Frontiers in Immunology.

TNB585.001: A multicenter, phase 1, open-label, dose-escalation and expansion study of tnb-585, a bispecific T-cell engager targeting PSMA in subjects with metastatic castrate resistant prostate cancer.

L. Fong, Duy Pham, U. Schellenberger, 2021 .

TNB-486 induces potent tumor cell cytotoxicity coupled with low cytokine release in preclinical models of B-NHL

Harbani K. Malik-Chaudhry, A. Boudreau, N. Trinklein, 2021, mAbs.

Multispecific Antibody Development Platform Based on Human Heavy Chain Antibodies

Michael J. Osborn, A. Boudreau, N. Trinklein, 2019, Front. Immunol..

Pre-clinical development of TNB-383B, a fully human T-cell engaging bispecific antibody targeting BCMA for the treatment of multiple myeloma.

N. Trinklein, S. F. Aldred, Duy Pham, 2018 .

T Cell Engagement without Cytokine Storm: A Novel Bcma x CD3 Antibody Killing Myeloma Cells with Minimal Cytokine Secretion

N. Trinklein, S. F. Aldred, Duy Pham, 2017 .

Multispecific Antibody Development Platform Based on Human Heavy Chain Antibodies.

Michael J. Osborn, A. Boudreau, N. Trinklein, 2019 .

Development of a fully human t-cell engaging bispecific antibody for the treatment of multiple myeloma.

N. Trinklein, S. F. Aldred, Duy Pham, 2017 .

TNB-486, a Novel Fully Human Bispecific CD19 x CD3 Antibody That Kills CD19-Positive Tumor Cells with Minimal Cytokine Secretion

A. Boudreau, N. Trinklein, S. F. Aldred, 2019, Blood.

Multispecific antibodies targeting CD38 show potent tumor-specific cytotoxicity.

A. Boudreau, N. Trinklein, S. F. Aldred, 2018 .